LRRC15 and renal cell carcinoma: Compared with TRS.Sig 33, PDL1.Sig 34, INFG.Sig 35, IMS.Sig 36, IMPRES.Sig 37, TcellExc.Sig 38, CRMA.Sig 39, LRRC15.CAF.Sig 40, and IPRES.Sig 41, the ROS-related signature showed the best predictive capability in the GSE126044 NSCLC cohort with an AUC of 0.91 (Fig. 8J) and achieved favorable performance in RCC, SKCM, and GBM cohorts (Fig. 8K), further demonstrating its potential as a predictive model of immune checkpoint blockade (ICB) response in LUAD and other types solid tumors.